Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC

(European Society for Medical Oncology) Data from two separate phase 3 studies to be presented at the ESMO 2017 Congress in Madrid, show alectinib's particular central nervous system (CNS) activity in patients with advanced non-small cell lung cancer involving a mutation of the anaplastic lymphoma kinase gene (ALK-positive NSCLC).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news